Posted inInfectious Diseases news Public Health
Nucleoside-Modified mRNA Influenza Vaccine Prevents Symptomatic and Febrile Illness in a Human Challenge Model
A phase 2a human challenge trial found a nucleoside‑modified mRNA influenza vaccine provided complete protection against symptomatic and febrile A/H1N1 infection versus unvaccinated controls and reduced viral load versus control and QIV, with no serious adverse events.